Reference 2019-38

REF:           2019-38

Subject:       Asthma patients

 

Request:

  1. In your trust, in the past 3 months [latest 3 months available], how many asthma  patients aged 18 and over have been treated [with a drug]?
  2. How many paediatric asthma treated patients [aged 6-17] have been treated in the last 3 months?
  3. How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated in the last 3 months?
  4. How many patients have been treated in the last 3 months with:

Omalizumab [Xolair]

Mepolizumab [Nucala]

Reslizumab [Cinqaero]

Benralizumab [Fasenra]

Other [Please state]

  1. How many paediatric patients have treated in the last 3 months with Xolair/omalizumab?
  2. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs ;

Ocreotide

Lanreotide

Pasireotide

Pegvisomant

 

 

Response:

1. In your trust, in the past 3 months [latest 3 months available], how many asthma patients aged 18 and over have been treated [with a drug]? Please find this information attached.

2019-38 – FOI Request – Asthma patients [12 kb] MS Excel

2. How many paediatric asthma treated patients [aged 6-17] have been treated in the last 3 months?
3. How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated in the last 3 months?
4. How many patients have been treated in the last 3 months with:
Omalizumab [Xolair] 13
Mepolizumab [Nucala] 0
Reslizumab [Cinqaero]
Benralizumab [Fasenra]
Other [Please state]
5. How many paediatric patients have treated in the last 3 months with Xolair/omalizumab? 0
6. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs:
Ocreotide 11
Lanreotide 2
Pasireotide 0
Pegvisomant 0